XML 25 R15.htm IDEA: XBRL DOCUMENT v3.25.2
Note 6 - Goodwill and Intangible Assets
9 Months Ended
Jun. 30, 2025
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

6. Goodwill and Intangible Assets

 

The Company conducts an impairment assessment annually on April 1, or more frequently if impairment indicators are present. The Company determined that a sustained decline in its stock price was an indicator of potential impairment and performed an interim quantitative goodwill impairment test for its reporting units as of June 30, 2025.

 

Based on the results of the interim quantitative impairment test performed as of June 30, 2025, the fair values of the Sample Management Solutions (“SMS”) and Multiomics reporting units exceeded their respective carrying amounts. The Company concluded that there was no impairment to goodwill for the SMS and Multiomics reporting units as of June 30, 2025. The estimated fair value of each of the reporting units was derived based on the income approach and the market approach which were weighted at 75% and 25%, respectively, as of June 30, 2025. The DCF Method was used in the income approach which reflected the Company’s assumptions regarding revenue growth rates, forecasted gross profit margins, operating expenses, capital expenditures, discount rates, terminal period growth rates, economic and market trends, and other expectations about the anticipated operating results of the SMS and Multiomics reporting units. The guideline company method was used in the market approach and publicly traded companies in similar lines of business were identified and used in an analysis to estimate the fair value.

 

Prior to the quantitative goodwill impairment test, the Company tested the recoverability of long-lived assets and other assets of the SMS and Multiomics reporting units and concluded that such assets were not impaired as of June 30, 2025.

 

​The following table sets forth the changes in the carrying amount of goodwill by operating and reportable segment since  September 30, 2024 (in thousands). 

 ​

  

Sample

         

 

Management

         
  

Solutions

  

Multiomics

  

Total

 

Balance - October 1, 2024

 $494,649  $196,760  $691,409 

Currency translation adjustments

  12,205      12,205 

Balance - June 30, 2025

 $506,854  $196,760  $703,614 

 

The components of the Company’s identifiable intangible assets as of June 30, 2025 and  September 30, 2024 are as follows (in thousands): 

 

 

June 30, 2025

  

September 30, 2024

 

 

  

Accumulated

  

Net Book

  

  

Accumulated

  

Net Book

 

 

Cost

  

Amortization

  

Value

  

Cost

  

Amortization

  

Value

 

Patents

 $1,220  $1,220  $  $1,227  $1,227  $ 

Completed technology

  111,681   61,411   50,270   109,949   55,191   54,758 

Trademarks and trade names

  734   271   463   726   195   531 

Customer relationships

  249,203   191,800   57,403   248,036   178,283   69,753 

Total

 $362,838  $254,702  $108,136  $359,938  $234,896  $125,042 

 

Amortization expenses for intangible assets were $6.2 million and $7.2 million, respectively, for the three months ended June 30, 2025 and 2024. Amortization expenses for intangible assets were $18.4 million and $21.6 million, respectively, for the nine months ended June 30, 2025 and 2024.

 

Estimated future amortization expense for the intangible assets for the remainder of fiscal year 2025 and the subsequent five fiscal years are as follows (in thousands):

 

Remainder of fiscal year 2025

 $6,239 

2026

  22,315 

2027

  17,887 

2028

  15,003 

2029

  12,386 

2030

  10,811